Nectin-4 导向的抗体药物偶联物 (ADC)：聚焦临床前和临床证据。
Nectin-4-directed antibody-drug conjugates (ADCs): Spotlight on preclinical and clinical evidence.
发表日期：2024 Jul 11
作者：
Mohammad Javad Khosravanian, Yousef Mirzaei, Ali Hussein Mer, Maryam Keyhani-Khankahdani, Fatemeh Sarina Abdinia, Fatemeh Misamogooe, Zahra Amirkhani, Nader Bagheri, Anna Meyfour, Saeed Jahandideh, Nesa Barpour, Yousef Nikmanesh, Hosein Shahsavarani, Meghdad Abdollahpour-Alitappeh
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS
摘要：
Nectin-4（Nectin 细胞粘附分子 4）是一种 I 型跨膜细胞粘附蛋白，已被证明在多种肿瘤中过度表达，使其成为抗体药物偶联物 (ADC) 等靶向治疗的有吸引力的抗原。值得注意的是，美国食品和药物管理局 (FDA) 批准首个 Nectin-4 导向的 ADC enfortumab vedotin (EV) 用于治疗尿路上皮癌 (UC)，不仅将 Nectin-4 作为经过临床验证的可靠靶点抗原，同时也证实了 Nectin-4 导向的 ADC 作为新颖且有前途的癌症疗法的不断发展的作用。除EV外，已经或目前分别有7种和11种Nectin-4导向的ADC处于临床试验和临床前开发的不同阶段，为Nectin-4阳性癌症患者的治疗提供了广阔的前景。本研究回顾了临床和临床前阶段 Nectin-4 导向的 ADC。版权所有 © 2024。由 Elsevier Inc. 出版。
Nectin-4 (Nectin cell adhesion molecule 4), a type I transmembrane cell adhesion protein, was demonstrated to be overexpressed in a variety of tumors, making it an attractive antigen for targeted therapies such as antibody-drug conjugates (ADCs). Of great note, the US Food and Drug Administration (FDA)-approval of the first Nectin-4-directed ADC, enfortumab vedotin (EV), in urothelial cancer (UC) not only introduced Nectin-4 as a clinically validated and reliable target antigen but also confirmed the evolving role of Nectin-4-directed ADCs as novel and promising cancer therapeutics. In addition to EV, there have been or are currently being seven and eleven Nectin-4-directed ADCs, respectively, in various stages of clinical trials and preclinical development, offering a promising future for the treatment of Nectin-4-positive cancer patients. This study reviewed clinical- and preclinical-stage Nectin-4-directed ADCs.Copyright © 2024. Published by Elsevier Inc.